Abstract | OBJECTIVES: METHODS: We studied 42 patients treated with anti- cytokine agents at our hospital: 31 had received a single agent, ten had received two agents and one had received three agents. Patients were divided into a TCZ group (22 patients) and a TNF inhibitor group (32 patients). The main parameters compared were treatment retention rate, serum amyloid A (SAA) profile, renal function profile and clinical disease activity index. RESULTS: The 5-year retention rates were 90.4 (TCZ group) and 34.3 % ( TNF inhibitor group) (p = 0.0154, log-rank test). The median SAA fell from 219.2 μg/mL at treatment initiation to 5.0 μg/mL at last observation (TCZ), and from 143.6 to 38.1 μg/mL ( TNF inhibitor) (p = 0.0194). Estimated glomerular filtration rate was improved in 72.7 (TCZ) and 34.4 % ( TNF inhibitor) of patients (p = 0.0062). The rates of clinical remission or low disease activity at last observation for the TCZ and TNF inhibitor groups were 72.7 and 40.7 % (p = 0.0201), respectively. CONCLUSIONS:
|
Authors | Yasuaki Okuda, Makoto Ohnishi, Kenichiro Matoba, Kazuo Jouyama, Akihiro Yamada, Naoya Sawada, Sho Mokuda, Yousuke Murata, Kiyoshi Takasugi |
Journal | Modern rheumatology
(Mod Rheumatol)
Vol. 24
Issue 1
Pg. 137-43
(Jan 2014)
ISSN: 1439-7609 [Electronic] England |
PMID | 24261770
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- tocilizumab
|
Topics |
- Aged
- Amyloidosis
(complications, drug therapy)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Retrospective Studies
- Rheumatic Diseases
(complications, drug therapy)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|